Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)

Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026

Journey Medical Corporation to Participate in September 2026 Investor Conferences